Compare SANG & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SANG | TIL |
|---|---|---|
| Founded | 1984 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.0M | 177.1M |
| IPO Year | 2021 | 2021 |
| Metric | SANG | TIL |
|---|---|---|
| Price | $5.37 | $10.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $100.67 |
| AVG Volume (30 Days) | 4.8K | ★ 69.7K |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $227,360,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.60 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.08 | $10.70 |
| 52 Week High | $7.99 | $42.79 |
| Indicator | SANG | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 56.96 | 36.08 |
| Support Level | $5.07 | $10.76 |
| Resistance Level | $5.42 | $11.51 |
| Average True Range (ATR) | 0.13 | 0.73 |
| MACD | 0.03 | 0.16 |
| Stochastic Oscillator | 91.26 | 2.71 |
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.